Access all of the content
Great to catch-up with Andrew Chan (Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland), who discussed challenges posed to patient care by COVID-19, factors to consider around immunosuppression for patients with multiple sclerosis (MS) during the pandemic, as well his personal thoughts on exciting developments in MS therapy and the 1st Virtual EAN Congress.
1. What are the challenges posed to patient care by COVID-19? (0:05)
2. What are the main factors to consider when assessing the risks and benefits of immunosuppression for MS during the pandemic? (1:44)
3. What have been the most exciting developments in MS therapy over the past year? (4:10)
4. What did you enjoy most at year’s Virtual EAN Congress? (5:29)
Speaker disclosure: Andrew Chan has served on advisory boards for, and received funding for travel or speaker honoraria from, Actelion-Janssen, Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and Teva, all for hospital research funds; and research support from Biogen, Genzyme and UCB. Andrew Chan holds a patent relating to mTOR inhibition as a mechanism to increase glucocorticoid efficacy, is associate editor of the European Journal of Neurology and serves on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!